Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2009

01-07-2009 | Clinical Trial

Comparing two objective methods for the aesthetic evaluation of breast cancer conservative treatment

Authors: Maria João Cardoso, Jaime S. Cardoso, Thomas Wild, Wilfried Krois, Florian Fitzal

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Login to get access

Abstract

Two programs were recently developed for the aesthetic evaluation of results in breast cancer conservative treatment: the Breast Cancer Conservative Treatment cosmetic results (BCCT.core) and the Breast Analyzing Tool (BAT). Both make use of a face-only photographic view of the patient and were developed to overcome the lack of reproducibility observed with subjective visual evaluation. The BCCT.core analyses several parameters related to asymmetry, color differences and scar appearance, while the BAT considers only asymmetry measurements. The purpose of this study was to compare the performance of these two methods. Material and methods Digital pictures of 59 patients from Porto and 60 from Vienna were evaluated subjectively by two panels using the four-class Harris scale. The Porto photographs had a similar backlight and better quality, and were evaluated by an international panel of 23 experts. The Vienna photographs had different backlight and lower quality, and were evaluated by four students and two breast cancer specialists. All 119 cases were submitted to analysis using the BCCT.core and BAT. Agreement between the software programs and the subjective evaluation was calculated using kappa (k), weighted kappa statistics (wk) and error rate (er). Results In overall analysis, BCCT.core program obtained a better agreement with the subjective evaluation (k = 0.56; wk = 0,64; er = 0.20) than the BAT software (k = 0.39; wk = 0.46; er = 0.42) (P < 0.0007). Results were again better for the BCCT.core program, when analysing the photographs obtained in Porto (k = 0.71; wk = 0.78; er = 0.14) than for the BAT (k = 0.35; wk = 0.41; er = 0.51) (P < 0.0003) while no significant differences in agreement were obtained regarding the Vienna images (P > 0.1). Conclusions The results suggest that the inclusion of multiple parameters in image analyses of aesthetic results has the potential to improve results. However, picture quality is probably important for analysis of other features besides asymmetry.
Literature
1.
go back to reference Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241. doi:10.1056/NEJMoa022152 PubMedCrossRef Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241. doi:10.​1056/​NEJMoa022152 PubMedCrossRef
2.
go back to reference Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232. doi:10.1056/NEJMoa020989 PubMedCrossRef Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232. doi:10.​1056/​NEJMoa020989 PubMedCrossRef
5.
go back to reference Sacchini V, Luini A, Tana S et al (1991) Quantitative and qualitative cosmetic evaluation after conservative treatment for breast cancer. Eur J Cancer 27(11):1395–1400PubMedCrossRef Sacchini V, Luini A, Tana S et al (1991) Quantitative and qualitative cosmetic evaluation after conservative treatment for breast cancer. Eur J Cancer 27(11):1395–1400PubMedCrossRef
6.
go back to reference Vrieling C, Collette L, Bartelink E et al (1999) Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 45(3):667–676. doi:10.1016/S0360-3016(99)00215-1 PubMed Vrieling C, Collette L, Bartelink E et al (1999) Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 45(3):667–676. doi:10.​1016/​S0360-3016(99)00215-1 PubMed
7.
go back to reference Cardoso MJ, Cardoso J, Santos AC, Barros H, Oliveira MC (2005) Interobserver agreement and consensus over the esthetic evaluation of conservative treatment for breast cancer. Breast 15:52–57 Cardoso MJ, Cardoso J, Santos AC, Barros H, Oliveira MC (2005) Interobserver agreement and consensus over the esthetic evaluation of conservative treatment for breast cancer. Breast 15:52–57
8.
go back to reference Pezner RD, Lipsett JA, Vora NL, Desai KR (1985) Limited usefulness of observer-based cosmesis scales employed to evaluate patients treated conservatively for breast cancer. Int J Radiat Oncol Biol Phys 11(6):1117–1119PubMed Pezner RD, Lipsett JA, Vora NL, Desai KR (1985) Limited usefulness of observer-based cosmesis scales employed to evaluate patients treated conservatively for breast cancer. Int J Radiat Oncol Biol Phys 11(6):1117–1119PubMed
9.
go back to reference Pezner RD, Patterson MP, Hill LR et al (1985) Breast retraction assessment: an objective evaluation of cosmetic results of patients treated conservatively for breast cancer. Int J Radiat Oncol Biol Phys 11(3):575–578PubMed Pezner RD, Patterson MP, Hill LR et al (1985) Breast retraction assessment: an objective evaluation of cosmetic results of patients treated conservatively for breast cancer. Int J Radiat Oncol Biol Phys 11(3):575–578PubMed
10.
11.
go back to reference Van Limbergen E, Rijnders A, van der Schueren E, Lerut T, Christiaens R (1989) Cosmetic evaluation of breast conserving treatment for mammary cancer. 2. A quantitative analysis of the influence of radiation dose, fractionation schedules and surgical treatment techniques on cosmetic results. Radiother Oncol 16(4):253–267. doi:10.1016/0167-8140(89)90037-6 PubMedCrossRef Van Limbergen E, Rijnders A, van der Schueren E, Lerut T, Christiaens R (1989) Cosmetic evaluation of breast conserving treatment for mammary cancer. 2. A quantitative analysis of the influence of radiation dose, fractionation schedules and surgical treatment techniques on cosmetic results. Radiother Oncol 16(4):253–267. doi:10.​1016/​0167-8140(89)90037-6 PubMedCrossRef
12.
go back to reference Krishnan L, Stanton AL, Collins CA, Liston VE, Jewell WR (2001) Form or function? Part 2. Objective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy. Cancer 91(12):2282–2287. doi:10.1002/1097-0142(20010615)91:12<2282::AID-CNCR1259>3.0.CO;2-0PubMedCrossRef Krishnan L, Stanton AL, Collins CA, Liston VE, Jewell WR (2001) Form or function? Part 2. Objective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy. Cancer 91(12):2282–2287. doi:10.1002/1097-0142(20010615)91:12<2282::AID-CNCR1259>3.0.CO;2-0PubMedCrossRef
Metadata
Title
Comparing two objective methods for the aesthetic evaluation of breast cancer conservative treatment
Authors
Maria João Cardoso
Jaime S. Cardoso
Thomas Wild
Wilfried Krois
Florian Fitzal
Publication date
01-07-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0173-4

Other articles of this Issue 1/2009

Breast Cancer Research and Treatment 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine